Arlington Financial Advisors LLC Buys 35 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Arlington Financial Advisors LLC boosted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 7.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 535 shares of the pharmaceutical company’s stock after purchasing an additional 35 shares during the quarter. Arlington Financial Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $215,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in VRTX. Daymark Wealth Partners LLC grew its stake in Vertex Pharmaceuticals by 2.8% during the third quarter. Daymark Wealth Partners LLC now owns 804 shares of the pharmaceutical company’s stock valued at $374,000 after acquiring an additional 22 shares in the last quarter. Marcum Wealth LLC boosted its holdings in Vertex Pharmaceuticals by 2.2% in the 3rd quarter. Marcum Wealth LLC now owns 1,204 shares of the pharmaceutical company’s stock valued at $560,000 after purchasing an additional 26 shares during the period. Wedmont Private Capital increased its holdings in shares of Vertex Pharmaceuticals by 2.0% in the third quarter. Wedmont Private Capital now owns 3,249 shares of the pharmaceutical company’s stock worth $1,458,000 after purchasing an additional 65 shares during the period. Sanibel Captiva Trust Company Inc. purchased a new stake in shares of Vertex Pharmaceuticals in the third quarter worth $248,000. Finally, Boston Common Asset Management LLC boosted its stake in Vertex Pharmaceuticals by 34.9% during the third quarter. Boston Common Asset Management LLC now owns 50,266 shares of the pharmaceutical company’s stock valued at $23,378,000 after buying an additional 13,008 shares during the period. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Wall Street Analyst Weigh In

VRTX has been the topic of a number of research analyst reports. Piper Sandler decreased their target price on Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating on the stock in a research note on Monday, January 27th. JPMorgan Chase & Co. lowered their target price on shares of Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating on the stock in a research note on Monday, December 23rd. Scotiabank boosted their price target on shares of Vertex Pharmaceuticals from $430.00 to $433.00 and gave the stock a “sector perform” rating in a research note on Friday, January 31st. William Blair reissued an “outperform” rating on shares of Vertex Pharmaceuticals in a report on Friday, January 31st. Finally, Barclays dropped their price objective on shares of Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating for the company in a report on Friday, December 20th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $502.58.

Vertex Pharmaceuticals Stock Performance

VRTX opened at $469.32 on Friday. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The business has a 50 day simple moving average of $435.84 and a two-hundred day simple moving average of $462.87. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.